account* Glaxo will pay $60 mln in upfront payment and 20 pct stake LONDON, Oct 29 (Reuters) - GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) said it had licensed Amicus Therapeutics' (FOLD.O: Quote, Profile, Research, Stock Buzz) Amigal, which...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE 1-Glaxo licenses Amicus' Fabry disease drug
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account